Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vincent J. Angotti
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 12
- Beta
- 0.69
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -23.34
Financials
Revenue
$0.00-100.0%Net Income
$-4.31MEBITDA
$-3.36MFree Cash Flow
$-3.92MEPS (diluted)
$-0.06Shares Outstanding (diluted)
75.53M+3233.1%Operating Expenses
$3.92MCash & Debt
$17.08MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $28.0K | $-14.29M | $-0.34 |
| 2024 | $0.00 | $-13.00M | $-0.50 |
| 2023 | $651.0K | $-18.40M | $-1.29 |
| 2022 | $0.00 | $42.52M | $5.73 |
| 2021 | $378.0K | $-35.10M | $-5.86 |
| 2020 | $5.42M | $-40.38M | $-9.47 |
| 2019 | $2.29M | $-53.24M | $-13.45 |
| 2018 | $2.15M | $-47.15M | $-16.14 |
| 2017 | $8.00M | $-51.51M | $-21.97 |
| 2016 | $17.36M | $-43.16M | $-19.05 |
| 2015 | $19.26M | $-24.40M | $-11.93 |
| 2014 | $5.22M | $-33.35M | $-18.20 |
| 2013 | $29.50M | $-23.43M | $-11.80 |
| 2012 | $2.39M | $-33.36M | $-30.16 |
Valuation
TLPHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·33d ago·Neutral
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.06 per share
Typical surprise +20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.06 vs $-0.06beat
- Wed, May 13$-0.04 vs $-0.07beat
- Mon, Mar 23$-0.06 vs $-0.07beat
- Wed, Nov 12$-0.11 vs $-0.07miss
- Thu, Aug 14$-0.10 vs $-0.12beat
- Wed, May 14$-0.10 vs $-0.17beat
Estimates and results for TLPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLPH officers and directors.
- Bought
- $459k
- Sold
- $119
14 trades
1 trade
- Angotti Vincent J.bought
- Angotti Vincent J.bought
- Aslam Shakilbought
- Dasu Badri Nbought
- Asadorian Raffibought
- Angotti Vincent J.bought
- Angotti Vincent J.bought
- Asadorian Raffisold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLPH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.